ETF Series Solutions Trust Range Cancer Therapeutics ETF
CNCR
CNCR was delisted on the 27th of May, 2025.
23 hedge funds and large institutions have $12.5M invested in ETF Series Solutions Trust Range Cancer Therapeutics ETF in 2018 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 9 increasing their positions, 8 reducing their positions, and 7 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 8
0.14% more ownership
Funds ownership: 22.16% → 22.3% (+0.14%)
3% less capital invested
Capital invested by funds: $12.8M → $12.5M (-$378K)
18% less funds holding
Funds holding: 28 → 23 (-5)
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
BCWM LLC
Overland Park,
Kansas
|
+$433K |
| 2 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$372K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$245K |
| 4 |
OC
Oppenheimer & Co
New York
|
+$199K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$84.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$338K |
| 2 |
WCA
Waratah Capital Advisors
Toronto,
Ontario, Canada
|
-$332K |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$323K |
| 4 |
PCM
Prelude Capital Management
New York
|
-$291K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$284K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SPC
26
Sigma Planning Corp
Ann Arbor,
Michigan
| – | -$232K | -9,618 | Closed |
|
|
WAP
27
Wealthcare Advisory Partners
West Chester,
Pennsylvania
| – | -$39K | -1,600 | Closed |
|
28
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
| – | -$21K | -858 | Closed |
|
|
GT
29
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$17K | -700 | Closed |
|
30
CIBC Private Wealth Group
Atlanta,
Georgia
| – | -$12K | -505 | Closed |
|
CNCR Hedge Fund Activity: Q3 2018 in Review
23 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) for Q3 2018, worth a combined $12.5M — down 2.9% from $12.8M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CNCR and 2 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 9 added.
The largest buyer was BCWM LLC, adding an estimated $433K. The largest seller was Jane Street, cutting an estimated $338K.
- 23 institutional investors held ETF Series Solutions Trust Range Cancer Therapeutics ETF (CNCR) as of Q3 2018, down from 28 in Q2 2018.
- Funds reported $12.5M of ETF Series Solutions Trust Range Cancer Therapeutics ETF stock for Q3 2018, down 2.9% quarter-over-quarter.
- 2 funds opened new ETF Series Solutions Trust Range Cancer Therapeutics ETF positions in Q3 2018 and 7 closed out, a net change of -5 holders.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF buyer in Q3 2018 was BCWM LLC, an estimated $433K added.
- The largest ETF Series Solutions Trust Range Cancer Therapeutics ETF seller in Q3 2018 was Jane Street, an estimated $338K sold.
Based on aggregated 13F filings for Q3 2018.